Literature DB >> 11865675

Increasing throughput in lead optimization in vivo toxicity screens.

Vincent Meador1, William Jordan, John Zimmermann.   

Abstract

Lead optimization requires toxicity screening strategies to select a compound with a high likelihood of successful development. As numerous compounds need to be screened and resources to direct toward any single compound are limited, short turnaround times to generate and interpret data are needed. Utilization of in vivo toxicity screens is necessary for an effective screening strategy, however, if not appropriately implemented, they may consume excessive resources and prolong selection of a developable compound. Optimization of in vivo studies requires identifying effective placement into the screening strategy, selecting the appropriate study designs, implementing processes that allow rapid data generation and interpretation, and understanding the utilities of in vivo data. When implemented, an effective, high-throughput screening strategy will utilize adequate but minimal amounts of resources, and will prioritize processing near technical time limits. These require generating only the data from which decisions will be made and can be best achieved using as few animals as possible per study.

Entities:  

Mesh:

Year:  2002        PMID: 11865675

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  4 in total

Review 1.  The High Cost of Stroke and Stroke Cytoprotection Research.

Authors:  Paul A Lapchak; John H Zhang
Journal:  Transl Stroke Res       Date:  2016-12-30       Impact factor: 6.829

Review 2.  Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.

Authors:  J Thomas Peterson
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

3.  Workgroup report: Implementing a national occupational reproductive research agenda--decade one and beyond.

Authors:  Christina C Lawson; Barbara Grajewski; George P Daston; Linda M Frazier; Dennis Lynch; Melissa McDiarmid; Eisuke Murono; Sally D Perreault; Wendie A Robbins; Megan A K Ryan; Michael Shelby; Elizabeth A Whelan
Journal:  Environ Health Perspect       Date:  2006-03       Impact factor: 9.031

4.  Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.

Authors:  K-C Cheng; Walter A Korfmacher; Ronald E White; F George Njoroge
Journal:  Perspect Medicin Chem       Date:  2007-06-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.